Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Increases Straight Bond by CHF 150 Million
20.04.2023 / 18:30 CET/CEST
Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 million, in line with its financing plan for 2023. The increment has the same maturity (6.5 years) and coupon (2.100%) as the initial issuance.
The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the SIX Swiss Exchange. The proceeds of the bonds will be used for refinancing and general corporate purposes.
Key Data
Issue Size 6.5-Year Bond: CHF 150 million
Expected Payment Date: 04 May 2023
Maturity: 12 September 2029
Issue Price: 98.961 percent
Redemption Price: 100 percent
Coupon: 2.100 percent p.a.
Joint Lead Managers: Credit Suisse AG, UBS AG and Zürcher Kantonalbank
About Lonza
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our unparalleled breadth of offerings across divisions enables our customers to commercialize their discoveries and innovations in the healthcare industry.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 17,500 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 6.2 billion with a CORE EBITDA of CHF 2.0 billion in Full-Year 2022. Find out more at www.lonza.com
Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter
Lonza Contact Details
Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283 victoria.morgan@lonza.com
Lyle Wheeler
Investor Relations
Lonza Group Ltd
Tel +41 79 154 9522 lyle.wheeler@lonza.com
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;
- capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients;
- small molecule drug substances (13.2%);
- technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%);
- other (2.8%).
Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).